Jobs
-
Amneal Pharmaceuticals announced that the FDA has approved the company’s ANDA for a generic version of Teva’s ProAir HFA albuterol MDI for the treatment of asthma. Amneal submitted the ANDA in 2023 and was sued… Read more . . .
-
US-based start-up CorriXR Therapeutics has announced a partnership with inhaled drug developer InhaTarget Therapeutics and device developer Merxin Ltd for development of an inhaled gene therapy for the treatment of lung cancer. InhaTarget will use its lipid… Read more . . .
-
Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules (glycopyrronium / formoterol / budesonide) and Glenmark Airz FB Smartules (formoterol / budesonide) ampules for the treatment of COPD in India. According to the company, a clinical trial… Read more . . .
-
According to Blue Lake Biotechnology, the FDA has agreed to lift a partial clinical hold on a Phase 1/2a clinical trial of BLB201 intranasal RSV vaccine in children aged 8 months to 59 months with… Read more . . .
-
Nasus Pharma announced that it has initiated a Phase 2 study of the company’s NS002 epinephrine nasal powder, which the company is developing for the treatment of anaphylaxis. The open-label PK trial is expected to… Read more . . .
-
According to ReCode Therapeutics, the FDA has cleared the 3rd part of an ongoing Phase 2 trial of nebulized RCT2100 CFTR mRNA therapy in cystic fibrosis patients, and enrollment has opened at US sites. The new… Read more . . .
-
Scottish device developer 1nhaler has announced the closing of a £1.5 million funding led by Archangels, with proceeds intended for continued development the company’s disposable single-use dry powder inhaler. The company says that funds will… Read more . . .
-
Nebulizer maker Aerogen and inhaled interferon developer Synairgen have entered a strategic partnership for development of a custom device for delivery of Synairgen’s SNG001 inhaled interferon-beta, the companies have announced, noting that the new agreement… Read more . . .
-
According to Glenmark Pharmaceuticals, China’s National Medical Products Administration (NMPA) has approved Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of allergic rhinitis. Grand Pharmaceuticals, which acquired the Chinese rights to Ryaltris… Read more . . .
-
MannKind Corporation announced that it has discontinued the Phase 3 ICoN-1 study of MNKD-101 nebulized clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease “due to futility” after analysis of data from the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland